Bis(4-hydroxyphenyl)sulfone


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D000072660 Teratozoospermia PMID:34838688
MESH:D000078064 Gestational Weight Gain PMID:31864031
MESH:D000230 Adenocarcinoma PMID:30102602
MESH:D001008 Anxiety Disorders PMID:31301325; PMID:32044495
MESH:D001724 Birth Weight PMID:30696509
MESH:D002869 Chromosome Aberrations PMID:27472198
MESH:D003108 Colonic Diseases PMID:38908815
MESH:D003924 Diabetes Mellitus, Type 2 PMID:31663775
MESH:D004487 Edema PMID:36805134
MESH:D005234 Fatty Liver PMID:35561261
MESH:D005393 Fish Diseases PMID:35595038
MESH:D006130 Growth Disorders PMID:26606162
MESH:D006529 Hepatomegaly PMID:31424294; PMID:39298647
MESH:D006937 Hypercholesterolemia PMID:27241191
MESH:D006943 Hyperglycemia PMID:31344369; PMID:32203925
MESH:D006965 Hyperplasia PMID:29526645
MESH:D007037 Hypothyroidism PMID:36822074
MESH:D007153 Immunologic Deficiency Syndromes PMID:29195089
MESH:D007248 Infertility, Male PMID:35595038
MESH:D008569 Memory Disorders PMID:32045791
MESH:D009135 Muscular Diseases PMID:38348707
MESH:D009336 Necrosis PMID:29199064
MESH:D009410 Nerve Degeneration PMID:34474090; PMID:39577800
MESH:D009765 Obesity PMID:30557812; PMID:38588857
MESH:D009845 Oligospermia PMID:34838688
MESH:D010049 Ovarian Diseases PMID:37002642
MESH:D011297 Prenatal Exposure Delayed Effects PMID:30696509; PMID:35595038
MESH:D011470 Prostatic Hyperplasia PMID:30822521
MESH:D011471 Prostatic Neoplasms PMID:30822521
MESH:D013733 Testicular Diseases PMID:33098627; PMID:38348707
MESH:D013959 Thyroid Diseases PMID:37487893
MESH:D015430 Weight Gain PMID:27241191; PMID:29909315; PMID:30145421; PMID:31344369; PMID:34838688; PMID:35561261; PMID:37002642; PMID:39298647
MESH:D015431 Weight Loss PMID:33098627; PMID:37357847
MESH:D017180 Tachycardia, Ventricular PMID:25723814
MESH:D018149 Glucose Intolerance PMID:31344369
MESH:D018476 Hypokinesia PMID:29923629
MESH:D018487 Ventricular Dysfunction, Left PMID:31685870; PMID:37611474
MESH:D018879 Ventricular Premature Complexes PMID:25723814
MESH:D019465 Craniofacial Abnormalities PMID:36805134
MESH:D019954 Neurobehavioral Manifestations PMID:39577800
MESH:D020964 Embryo Loss PMID:27472198; PMID:29397701
MESH:D030342 Genetic Diseases, Inborn PMID:35595038
MESH:D050171 Dyslipidemias PMID:38588857
MESH:D056128 Obesity, Abdominal PMID:31528831
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:29199064; PMID:30660906; PMID:38348707
MESH:D062788 Adenomyosis PMID:37234927
MESH:D063766 Pediatric Obesity PMID:31528831
MESH:D064806 Dysbiosis PMID:38588857; PMID:38908815

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.